Guidance for manufacturers of artificial heart valves. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Similar Posts
Field Safety Notices: 25 to 29 August 2025
List of Field Safety Notices from 25 to 29 August 2025.
Class 2 Medicines Recall: Fucidin 250 mg Tablets, LEO Laboratories Ltd trading as LEO Pharma, EL(25)A/38
LEO Pharma is recalling the affected batch as a precautionary measure due to out of specification results for impurities during routine stability testing.
Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.
Decentralised Manufacture: Labelling
Guidance on labelling requirements pertinent to the type of medicinal product and its supply status, as defined in UK legislation.
MHRA seeks input on AI regulation at ‘pivotal moment’ for healthcare
National Commission is seeking evidence to shape regulation of AI in healthcare and support the UK’s ambition for a world-leading, AI-enabled NHS
Statutory guidance: MHRA fees
Fees payable to the MHRA from 2025.